I will do all I can to protect my patients from relapse

The first and only FDA approved oral maintenance therapy shown to cut the risk of high-risk neuroblastoma relapse in half.

Introducing IWILFIN

References:

1. IWILFIN. Prescribing information. USWM, LLC; 2023